

- 29 -

**Claims**

1. A peptide having an amino acid sequence of Formula I (SEQ ID NO: 1):

**X<sub>1</sub> [Lys X<sub>2</sub> X<sub>3</sub> Phe Gln]<sub>m</sub> Arg Gln Ile [Lys X<sub>4</sub> Pro Phe Gln]<sub>n</sub> X** in which

5 **X<sub>1</sub>** is absent or is an acetyl group;

**X<sub>2</sub>** and **X<sub>4</sub>** are independently selected from Ileu and Leu;

**X<sub>3</sub>** is selected from Pro and Trp;

**X** is a peptidic moiety of a length selected from 1, 2, 3, 4, 5, 6, 7 and 8 amino acids and containing at least one basic amino acid and which is amidated at the C-terminus;

10 **m** is an integer selected from 0 and 1;

**n** is an integer selected from 1 and 2;

as well as salt thereof.

15 2. A peptide according to claim 1, wherein **X** is a peptidic moiety of a length selected from 5, 6, 7 and 8 amino acids and containing at least one basic amino acid.

3. A peptide according to any of the preceding claims, wherein **X** contains at least one basic amino acid selected from Lys and Arg.

20 4. A peptide according to any of the preceding claims, wherein **X** is the following peptidic moiety (SEQ ID NO: 2):

**Asn X<sub>5</sub> X<sub>6</sub> Met X<sub>7</sub> Trp X<sub>8</sub> X<sub>9</sub> -NH<sub>2</sub>** wherein

**X<sub>5</sub>, X<sub>6</sub>, X<sub>7</sub>, X<sub>8</sub> and X<sub>9</sub>** are independently selected from Arg and Lys.

25 5. A peptide according to any of the preceding claims wherein **X** is of SEQ ID NO: 10.

6. A peptide according to claim 1, wherein **m** is 0 and **n** is 1.

7. A peptide according to claim 1 wherein **X<sub>1</sub>** is acetyl.

- 30 -

8. A peptide according to claim 1, wherein m is 0 and n is 2.

9. A peptide according to claim 1, wherein m is 1 and n is 1.

5 10. A peptide according to any claims from 1 to 9 selected from SEQ ID NO: 7 and SEQ ID NO: 8.

11. A peptide according to any claims from 1 to 10 for use as a medicament.

10 12. A pharmaceutical composition comprising a peptide according to any one of claims 1 to 10 and a pharmaceutically acceptable excipient, diluent or carrier.

13. Use of a peptide according to Formula (II) (SEQ ID NO: 3):

$X_1 [Lys X_2 X_3 Phe Gln]_m Arg Gln Ile [Lys X_4 X_5 Phe Gln]_n X$  in which

15  $X_1$  is absent or is an acetyl group;

$X_2$  and  $X_4$  are independently selected from Ile and Leu;

$X_3$  and  $X_5$  are independently selected from is Pro and Trp;

X is a peptidic moiety of 1, 2, 3, 4, 5, 6, 7 and 8 amino acids and containing at least one basic amino acid and which is amidated at the C-terminus;

20 m is an integer selected from 0 and 1;

n is an integer selected from 1 and 2;

as well as salts thereof for the preparation of a medicament for the treatment or prevention of a disease or condition selected from Alzheimer's disease, Dementia pugilistica (including head trauma), Hereditary Cerebral Haemorrhage with amyloidosis of the Dutch type (HCHWA-D) and vascular dementia with amyloid angiopathy.

25 14. Use according to claim 13 wherein  $X_5$  is Trp.

- 31 -

15. Use according to claim 13 wherein the peptide according to Formula (II) is of SEQ ID: 1.

16. Use according to claim 13 wherein X<sub>4</sub> is Ile.

5

17. Use according to claim 13 wherein X is a peptidic moiety of a length selected from 5, 6, 7 and 8 amino acids and containing at least one basic amino acid.

18. Use according to any claims from 13 to 17 wherein X contains at least one basic amino acid selected from Lys and Arg.

10

19. Use according to any claims from 13 to 18 wherein X is the peptidic moiety (SEQ ID NO: 2) as defined above; or a derivative or analog thereof.

20. Use according to any claims from 13 to 19 wherein X is of SEQ ID NO: 10.

15

21. Use according to claim 13, wherein m is 0 and n is 1.

22. Use according to any of the preceding claims from 13 to 21 wherein X<sub>5</sub> is Trp, X is the peptidic moiety of SEQ ID NO: 2 as defined above, m is 0 and n is 1.

20

23. Use according to claim 13, wherein m is 1 and n is 1.

24. Use according to any claims from 13 to 23 wherein the peptide is of SEQ ID NO: 4.

25

25. Use according to any claims from 13 to 24 wherein the peptide is selected from SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9).

- 32 -

26. Use according to any of the preceding claims from 13 to 25, wherein the disease is Alzheimer's disease.